Following the introduction of a new formulation of the reagents used in our laboratory to measure the concentration of vitamin B12 and folate in serum, we found that results were lower than those obtained with the previous reagents. Although the reagents' manufacturer provides new reference intervals (RI) for both magnitudes and they are also described in the literature, excessively pathological low values were observed in apparently healthy individuals.
To the Editor, Following the introduction of a new formulation of the reagents used in our laboratory to measure the concentration of vitamin B12 and folate in serum, we found that results were lower than those obtained with the previous reagents. Although the reagents' manufacturer provides new reference intervals (RI) for both magnitudes and they are also described in the literature, excessively pathological low values were observed in apparently healthy individuals.
First, we attempted to verify the RI proposed by the manufacturer following the Clinical and Laboratory Standards Institute (CLSI) document C28-A3 [1] . Twenty percent of the tested values (from 25 healthy individuals) were outside the proposed intervals. Based on this finding, we decided to elaborate our own RI.
To establish the vitamin B12 and folate RIs, the recommendations of the IFCC-CLSI were followed [1] : we prospectively selected a minimum of 120 reference individuals of legal age. They were mainly healthy workers belonging to different services of Parc Taulí University Hospital, as well as residents of Vallès-Occidental (Catalonia, Spain).
The study was approved by our hospital's Ethics and Clinical Research Committee. All patients gave written informed consent, approving all examinations and procedures. Their anonymity was maintained.
To select the reference population, multiple exclusion criteria were established allowing us to detect situations that could cause an alteration in the metabolism of these vitamins. These criteria include low dietary consumption, malabsorption, increased requirements, increased losses and chronic use of certain drugs or vitamins [2] . This information was obtained from medical records. Also, a questionnaire was used to establish participants' lifestyle, such as physical exercise habits, consumption of alcohol and toxins, and dietary needs and habits.
Samples were collected and processed between October 2016 and February 2017. All of them were analyzed on the day of the extraction. The vitamin B12 and folate concentrations were measured in serum sample tubes with separator gel by an electrochemiluminescence immunoassay on an automated analyser (cobas 8000 e801, Roche Diagnostics, Mannheim, Germany). The reagents employed were the Roche Diagnostics Folate assay, traceable to the WHO International Standard-National Institute of Biological Standards and Control (NIBSC) code 03/178, and Roche Elecsys Vitamin B12 II standardised with Elecsys Vitamin B12 test.
The distribution of the data was analyzed using the Kolmogorov-Smirnov test. The lower and upper reference limits are estimated as the 2.5th and 97.5th percentiles of the distribution of test results for the reference population, respectively.
The outliers were eliminated by the Grubbs' test. All statistical calculations were performed using the statistical program Medcalc ® Version 7.2.1.0.
To discover whether it would be necessary to generate RI according to age and sex, we used the Harris and Boyd partition criteria [3, 4] . If one of these criteria is met, the sample will need to be increased up to 240 individuals.
Once the new RI are separated by sex or age, it will be necessary to test for statistically significant differences between the new RI of the different groups using the Wilcoxon test (α = 0.05).
The within-day imprecision was calculated for both analytes during the entire study period to guarantee the optimal analytical conditions established by our laboratory. The authors stipulated that the maximum imprecision allowed must be less than that obtained by the current state of the technology. Those results were collected from the UNITY inter-laboratory comparison quality control web (Biorad, CA, USA) for all laboratories that use the same method as ours [5] . We used data from the Anemia control, lot 43250, which showed an accumulated coefficient of variation (CV) of 10.2% for vitamin B12 and 31.3% for folate (the accumulated period since December 2015).
Vitamin B12: A group of 127 reference individuals (67 women, 59 men) between 19 and 83 years of age was initially included in the study. Four samples were discarded, three for presenting some exclusion criteria and another considered as an outlier, thus leaving a reference population of 123 individuals.
The within-day imprecision during the study period was CV1 = 3.91% (x̅ 1: 452 pg/mL) and CV2 = 3.64% (x̅ 2: 878 pg/mL).
The results of the Kolgomorov-Smirnoff test showed that the distribution of the population used for the vitamin B12 RI was Gaussian. According to the Harris and Boyd criteria, vitamin B12 does not require specific RI for age and sex ( Table 1 ). The RIs obtained for vitamin B12 were 150-695 pg/mL (111-513 pmol/L).
Folate: From the original population of 127 reference individuals, one was discarded because it was identified as an outlier, leaving a total of 126 reference individuals.
The within-day imprecision observed was CV1 = 5.76% (x̅ 1: 4.49 ng/mL) and CV2 = 4.68% (x̅ 2: 11.60 ng/mL).
The Kolmogorov-Smirnoff test showed a non-Gaussian distribution for this population.
According to the Harris and Boyd criteria, it was necessary to differentiate based on age (Table 1) . Regarding the partition by age, we selected the age of 45 years as a cut-off point. This value was chosen following bibliographic criteria considering that a higher incidence of folate deficiency is observed in individuals less than 50 years of age [6, 7] . This value was in accordance with our population size.
Based on these results, we extended the reference population to 246 individuals, 120 younger than 45 years and 126 equal to or over 45 years of age.
The sample processing period was extended until October 2017. The total imprecision observed during this period was CV1 = 5.48% (concentration range between 4.28 and 4.72 ng/mL) and CV2 = 5.29% (concentration range between 11.1 and 12.4 ng/mL). These different ranges are due to the different batch control used during the period of the study. Statistically significant differences (p < 0.05) were found by the Wilcoxon test between the folate RIs for the group under 45 years of age and those who were over 45 years of age.
The RIs obtained for folate were 2-13.85 ng/mL (4.54-31.44 nmol/L) for individuals under 45 years old and 2.9-16.64 ng/mL (6.58-37.77 nmol/L) for those over 45 years old.
In conclusion, RIs obtained, as shown in Table 2 , are lower than those proposed by the manufacturer for both vitamin B12 (suggested RI 197-771 pg/mL [145-569 pmol/L]) and folate (suggested RI 3.89-26.8 ng/mL [6.56-60.84 nmol/L]). Besides, the manufacturer did not contemplate age differences. The implementation of a new RI has been especially relevant in the case of folate deficiency. As a result of this study, we have detected higher concentrations of folate in the over 45 years old population, as other authors has reported [6, 7] .
The study published recently by Ferraro et al. [8] , which used the same measurement procedure as ours, also reported considerably higher folate concentrations as population age increases.
Our results show the importance of each laboratory developing its own RI, especially important in the case of biochemical magnitudes that are highly influenced by diet, such as vitamins. Depending on the geographical region and the environmental and dietary factors of the reference population, blood concentrations vary significantly.
There is controversy because some authors recommend the substitution of RI for a cut-off to classify the risk of vitamin deficiency [9] , but a wide variety of different cut-offs are proposed [10] . Nowadays there is not an international consensus.
The implementation of these new RI has allowed a better classification of patients previously classed as hypovitaminosis without associated clinical signs.
